... Health Secretary Sajid Javid said two studies suggesting omicron carries a significantly lower risk of hospitalization than the previously dominant delta strain was “encouraging news.” But he said it was “not very clear yet ... by how much that risk is reduced.” ...
This authorization is more limited than one on Wednesday for a Pfizer pill. The FDA authorized the Merck pill, developed with Ridgeback Biotherapeutics, for high-risk adults "for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."
Three separate teams of scientists on two continents have found that Omicron infections more often result in mild illness than earlier variants of the coronavirus, offering hope that the current surge may not be quite as catastrophic as feared despite skyrocketing caseloads.
The researchers examined Omicron’s course through populations in South Africa, Scotland and England. The results in each setting, while still preliminary, all suggested that the variant was less likely to send people in hospitals.
“Given that this is everywhere and given that it’s going to be so transmissible, anything that would lower severity is going to be better,” said Natalie Dean, a biostatistician at Emory University in Atlanta.
The Supreme Court will hear legal challenges to the Biden administration's employer vaccine mandates next month, the justices announced Wednesday night, setting a rapid schedule for the cases.
WASHINGTON (AP) — U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.
Recent Comments